These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

10105 related articles for article (PubMed ID: 12727113)

  • 41. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
    Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
    Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
    Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Allogeneic tumor vaccine produced by electrofusion between osteosarcoma cell line and dendritic cells in the induction of antitumor immunity.
    Yu Z; Ma B; Zhou Y; Zhang M; Long H; Wang Y; Fan Q
    Cancer Invest; 2007; 25(7):535-41. PubMed ID: 17952746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity.
    Takeda A; Homma S; Okamoto T; Kufe D; Ohno T
    Eur J Clin Invest; 2003 Oct; 33(10):897-904. PubMed ID: 14511362
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage.
    Labeur MS; Roters B; Pers B; Mehling A; Luger TA; Schwarz T; Grabbe S
    J Immunol; 1999 Jan; 162(1):168-75. PubMed ID: 9886383
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice.
    Khamisabadi M; Arab S; Motamedi M; Khansari N; Moazzeni SM; Gheflati Z; Hadjati J
    Iran J Immunol; 2008 Mar; 5(1):36-44. PubMed ID: 18319523
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Truncated TERT mRNA transfected dendritic cells evoke TERT specific antitumor response in vivo.
    Qiu J; Lil GW; Sui YF; Sun YJ; Huang YY; Si SY; Ge W; Song HP
    Hepatogastroenterology; 2007; 54(75):681-7. PubMed ID: 17591041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
    He T; Tang C; Xu S; Moyana T; Xiang J
    Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
    Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
    J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor cell lysates as immunogenic sources for cancer vaccine design.
    González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
    Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antitumor Effect of KML-B-Treated Dendritic Cells via Induction of Lymphocyte Activation.
    Kim JJ; Hwang YH; Kang KY; Lee SJ; Kim JB; Choi J; Yee ST
    J Immunol Res; 2017; 2017():2471627. PubMed ID: 28634588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.
    Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
    Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity.
    Shibagaki N; Udey MC
    J Immunol; 2002 Mar; 168(5):2393-401. PubMed ID: 11859130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
    van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
    J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 506.